Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1347-1356

  He, Rong ^a   Chen, Yufeng ^a   Chen, Yihua ^a   Ougolkov, Andrei V ^b,c   Zhang, Jin San ^b   Savoy, Doris N ^b   Billadeau, Daniel D ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Department of Health Sciences Research   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [1 (3 FLUORO 4 METHOXYPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (3,5 BIS HYDROXYMETHYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (3,5 DIFLUOROPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 AMINOPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 HYDROXYMETHYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 IODOPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 NITROPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 TERT BUTYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 (4 TRIFLUOROMETHYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; 7 [3 [1 CYCLOHEXYL 1H [1,2,3]TRIAZOL 4 YL]PHENYLCARBAMOYL]HEPTANOIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OCTANEDIOIC ACID [3 [1 (3 AMINOPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 (3 FLUORO 4 METHOXYPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 (3,5 BIS(HYDROXYMETHYL)PHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 (3,5 DIFLUOROPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 (4 FLUOROPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 (4 TERT BUTYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID [3 [1 CYCLOHEXYL 1H [1,2,3]TRIAZOL 4 YL]PHENYL]AMIDE HYDROXYAMIDE; OCTANEDIOIC ACID HYDROXYAMIDE [3 (1 (4 HYDROXYMETHYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL)PHENYL]AMIDE; OCTANEDIOIC ACID HYDROXYAMIDE [3 (1 (4 IODOPHENYL) 1H [1,2,3]TRIAZOL 4 YL)PHENYL]AMIDE; OCTANEDIOIC ACID HYDROXYAMIDE [3 (1 (4 TRIFLUOROMETHYLPHENYL) 1H [1,2,3]TRIAZOL 4 YL)PHENYL]AMIDE; OCTANEDIOIC ACID HYDROXYAMIDE [3 (1 PHENYL 1H [1,2,3]TRIAZOL 4 YL)PHENYL]AMIDE; ROMIDEPSIN; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77249176625     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901667k     Document Type: Article

References (45)

1. Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des. 2008, 14, 505-528.
2. Butler, R.; Bates, G. P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7, 784-796.
3. Jaenisch, R.; Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33, 245-254.
4. (a) Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
5. (b) Kurdistani, S. K.; Grunstein, M. Histone acetylation and deacetylation in yeast. Nat. Rev. Mol. Cell Biol. 2003, 4, 276-284.
6. (c) Struhl, K.; Moqtaderi, Z. The TAFs in the HAT. Cell 1998, 94, 1-4.
7. (d)Wolffe, A. P.; Guschin, D. Review: chromatin structural features and targets that regulate transcription. J. Struct. Biol. 2000, 129, 102-122.
8. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784.
9. Kummar, S.; Gutierrez, M.; Gardner, E. R.; Donovan, E.; Hwang, K.; Chung, E. J.; Lee, M. J.; Maynard, K.; Kalnitskiy, M.; Chen, A.; Melillo, G.; Ryan, Q. C.; Conley, B.; Figg, W. D.; Trepel, J. B.; Zwiebel, J.; Doroshow, J. H.; Murgo, A. J. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 2007, 13, 5411-5417.
10. Kozikowski, A. P.; Chen, Y.; Gaysin, A.; Chen, B.; D'Annibale, M. A.; Suto, C. M.; Langley, B. C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J.Med.Chem. 2007, 50, 3054-3061.
11. Kinzel, O.; Llauger-Bufi, L.; Pescatore, G.; Rowley, M.; Schultz-Fademrecht, C.; Monteagudo, E.; Fonsi, M.; Gonzalez, P. O.; Fiore, F.; Steinkühler, C.; Jones, P. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J. Med. Chem. 2009, 52, 3453-3456.
12. (a) Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H.; Phase, I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
13. (b) Carducci, M. A.; Gilbert, J.; Bowling, M. K.; Noe, D.; Eisenberger, M. A.; Sinibaldi, V.; Zabelina, Y.; Chen, T. L.; Grochow, L. B.; Donehower, R. C. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 2001, 7, 3047-3055.
14. (c) Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 2002, 64, 1079-1090.
15. (a) Liu, B.; Hong, J. S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304, 1-7.
16. (b) Lin, H. S.; Hu, C. Y.; Chan, H. Y.; Liew, Y. Y.; Huang, H. P.; Lepescheux, L.; Bastianelli, E.; Baron, R.; Rawadi, G.; Clâement-Lacroix, P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 2007, 150, 862-872.
17. (a) Hockly, E.; Richon, V. M.; Woodman, B.; Smith, D. L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P. A.; Steffan, J. S.; Marsh, J. L.; Thompson, L. M.; Lewis, C. M.; Marks, P. A.; Bates, G. P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 2041-2046.
18. (b) Levenson, J. M.; O'Riordan, K. J.; Brown, K. D.; Trinh, M. A.; Molfese, D. L.; Sweatt, J. D. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 2004, 279, 40545-40559.
19. (c) Fischer, A.; Sananbenesi, F.; Wang, X.; Dobbin, M.; Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447, 178-182.
20. Sasakawa, Y.; Naoe, Y.; Noto, T.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 2003, 66, 897-906.
21. (a) Dow, G. S.; Chen, Y. F.; Andrews, K. T.; Caridha, D.; Gerena, L.; Gettayacamin, M.; Johnson, J.; Li, Q.; Melendez, V.; Obaldia, N.; Tran, T. N.; Kozikowski, A. P. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 2008, 52, 3467-3477.
22. (b) Ouaissi, M.; Ouaissi, A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J. Biomed. Biotechnol. 2006, 2006, 13474.
23. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
24. (a) Luo, J.; Nikolaev, A. Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107, 137-148.
25. (b) Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone deacetylase inhibitors. Adv. Cancer Res. 2004, 91, 137-168.
26. Hu, E.; Dul, E.; Sung, C. M.; Chen, Z.; Kirkpatrick, R.; Zhang, G. F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 2003, 307, 720-728.
27. Villagra, A.; Cheng, F.; Wang, H. W.; Suarez, I.; Glozak, M.; Maurin, M.; Nguyen, D.; Wright, K. L.; Atadja, P. W.; Bhalla, K.; Pinilla-Ibarz, J.; Seto, E.; Sotomayor, E. M. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 2009, 10, 92-100.
28. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-488.
29. Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D. Rational development of histone deacetylase inhibitors as anti-cancer agents: a review. Mol. Pharmacol. 2005, 68, 917-932.
30. Gao, L.; Cueto, M. A.; Asselbergs, F.; Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277, 25748-25755.
31. (a) Guo, L.; Han, A.; Bates, D. L.; Cao, J.; Chen, L. Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 4297-4302.
32. (b) Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkühler, C.; Gallinari, P.; Carfí, A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 2008, 283, 26694-26704.
33. Rivieccio, M. A.; Brochier, C.; Willis, D. E.; Walker, B. A.; D'Annibale, M. A.; McLaughlin, K.; Siddiq, A.; Kozikowski, A. P.; Jaffrey, S. R.; Twiss, J. L.; Ratan, R. R.; Langley, B. HDAC6 is a target for protection and regeneration following injury in the nervous system.Proc.Natl.Acad. Sci.U.S.A. 2009, 106, 19599-19604.
34. Zhang, B.; West, E. J.; Van, K. C.; Gurkoff, G. G.; Zhou, J.; Zhang, X. M.; Kozikowski, A. P.; Lyeth, B. G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res. 2008, 1226c, 181-191.
35. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 2008, 51, 4370-4373.
36. Chen, Y.; Lopez-Sanchez, M.; Savoy, D. N.; Billadeau, D. D.; Dow, G. S.; Kozikowski, A. P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem. 2008, 51, 3437-3448.
37. (a) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
38. (b) Tornøe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057-3064.
39. Chen, Y.; He, R.; Chen, Y.; D'Annibale, M. A.; Langley, B.; Kozikowski, A. P. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. ChemMedChem. 2009, 4, 842-852.
40. Arnold, N. B.; Arkus, N.; Gunn, J.; Korc, M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin. Cancer Res. 2007, 13, 18-26.
41. Kumagai, T.; Wakimoto, N.; Yin, D.; Gery, S.; Kawamata, N.; Takai, N.; Komatsu, N.; Chumakov, A.; Imai, Y.; Koeffler, H. P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 2007, 121, 656-665.
42. Karagianni, P.; Wong, J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007, 26, 5439-5449.
43. Lâopez-Soto, A.; Folgueras, A. R.; Seto, E.; Gonzalez, S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009, 28, 2370-2382.
44. Schneider, G.; Reichert, M.; Saur, D.; Hamacher, R.; Fritsch, R.; Schmid, R. M. HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Proliferation 2007, 40, 522-531.
45. Sanda, T.; Okamoto, T.; Uchida, Y.; Nakagawa, H.; Iida, S.; Kayukawa, S.; Suzuki, T.; Oshizawa, T.; Suzuki, T.; Miyata, N.; Ueda, R. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21, 2344-2353.